Shanghai Junshi Biosciences Co., Ltd.SSE: 688180

(688180)"Shanghai Junshi Biosciences Co., Ltd."Announcement on Voluntary Disclosure of the Grant of Regular Approval by the National Medical Products Administration for Toripalimab for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma After Failure of Platinum-based Chemotherapy

· Issued by Shanghai Junshi Biosciences Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Stock code 688180 ·

On 6ix: 6ix.com/news/688180shanghai-junshi-biosciences-co-ltdannouncement-on-voluntary-disclosure-of-the-grant-of-regular-approval-by-the-national-medical-products-administration-for-toripalimab-for-the-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma-after-failure-of-platinum-based-chemotherapy

Announcement on Voluntary Disclosure of the Grant of Regular Approval by the National Medical Products Administration for Toripalimab for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma After Failure of Platinum-based Chemotherapy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

6ix is reading this filing.

View original source (Shanghai Stock Exchange)Shanghai Junshi Biosciences Co., Ltd. on 6ix

Story so far

Earlier from Shanghai Junshi Biosciences

Later from Shanghai Junshi Biosciences

All Shanghai Junshi Biosciences news releases